Euroapi
Euroapi, a leading player in the pharmaceutical industry, is headquartered in France and operates across major regions in Europe and beyond. Founded in 2022, the company has quickly established itself as a key provider of active pharmaceutical ingredients (APIs) and advanced drug delivery systems. With a focus on innovation and sustainability, Euroapi offers a diverse range of products and services that cater to the evolving needs of the healthcare sector. Their commitment to quality and regulatory compliance sets them apart in a competitive market. Recognised for their expertise in complex APIs, Euroapi has achieved significant milestones, positioning itself as a trusted partner for pharmaceutical companies worldwide. As the industry continues to evolve, Euroapi remains dedicated to advancing healthcare solutions through cutting-edge technology and strategic collaborations.
DitchCarbon Score
How does Euroapi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Euroapi's score of 58 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Euroapi's reported carbon emissions
In 2023, Euroapi reported total carbon emissions of approximately 63,317,000 kg CO2e from Scope 1, 27,371,000 kg CO2e from Scope 2, and 63,086,000 kg CO2e from Scope 3 emissions. This reflects a significant reduction in emissions compared to previous years, with Scope 1 emissions decreasing from about 74,043,000 kg CO2e in 2021 and Scope 2 emissions dropping from approximately 63,086,000 kg CO2e in the same year. The company has committed to near-term targets for reducing greenhouse gas emissions from its operations (Scopes 1 and 2), aligning with global efforts to limit warming. However, Euroapi has not yet set a net-zero target. Their emissions reduction initiatives are consistent with industry standards aimed at mitigating climate change impacts within the pharmaceuticals, biotechnology, and life sciences sector. Overall, Euroapi's emissions data and commitments demonstrate a proactive approach to addressing climate change while continuing to monitor and report on their environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 91,378,000 | 00,000,000 | 00,000,000 | 00,000,000 | - |
| Scope 2 | 100,953,000 | 00,000,000 | 00,000,000 | 00,000,000 | - |
| Scope 3 | 705,065,000 | 000,000,000 | 000,000,000 | 00,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Euroapi is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
